|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
L01 BB02
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
Purinethol
|
|
gptkbp:can_be_combined_with
|
gptkb:methotrexate
gptkb:cyclophosphamide
|
|
gptkbp:casnumber
|
50-44-2
|
|
gptkbp:chemical_formula
|
C6 H6 N4 S
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:contraindication
|
gptkb:disease
liver disease
pregnancy
|
|
gptkbp:developed_by
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:discovered_by
|
1953
|
|
gptkbp:dosage_form
|
2.5 mg/kg/day
50 mg/m2/day
|
|
gptkbp:formulation
|
gptkb:tablet
gptkb:liquid
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
mercaptopurine
|
|
gptkbp:interacts_with
|
gptkb:warfarin
gptkb:azathioprine
allopurinol
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
renal function tests
|
|
gptkbp:mechanism_of_action
|
purine analog
|
|
gptkbp:pharmacokinetics
|
excreted in urine
metabolized by xanthine oxidase
|
|
gptkbp:research_focus
|
gptkb:cancer_treatment
immunosuppressive therapy
|
|
gptkbp:side_effect
|
gptkb:anemia
nausea
vomiting
liver toxicity
thrombocytopenia
bone marrow suppression
increased risk of infection
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:suitable_for
|
active infections
severe renal impairment
severe hepatic impairment
|
|
gptkbp:treatment
|
gptkb:Oncology
|
|
gptkbp:used_for
|
treating autoimmune diseases
treating leukemia
|
|
gptkbp:bfsParent
|
gptkb:Lialda
|
|
gptkbp:bfsLayer
|
6
|